The rise of GLP-1 weight-loss drugs has created a problem that many employers never anticipated. GLP-1s have evolved into a major expense for corporate health plans. According to a recent Wall Street Journal article, large employers across the country are scaling back coverage, adding restrictions, or eliminating benefits for weight-loss use altogether. The reason is that demand has exploded, and the cost of paying for these drugs across a large workforce has become difficult to justify.
HCA Healthcare stopped covering GLP-1 medications for weight loss after usage among employees surged 90% in 2025. Blue Cross Blue Shield of Massachusetts projects that its GLP-1 costs could approach $1 billion this year, nearly double the previous year and seven times what it spent in 2023. Benefits consultants report that many employers are struggling with double-digit increases in medical and pharmacy expenses while also dealing with inflation, rising wages, and pressure on profits.
Wooing workers, though, has become less of a priority as companies’ spending on GLP-1 drugs has ballooned. HCA Healthcare, which employs more than 300,000 workers across its hospitals and medical centers, stopped covering the drugs for weight-loss use as of January after use of GLP-1s on its employee plan surged 90% in 2025, driving up its costs. Like most companies, it still covers it for diabetes.
Blue Cross Blue Shield of Massachusetts has stopped coverage of GLP-1s for obesity treatment in the plans it sells to employers, too. As of January, employers can instead buy the coverage as an add-on, and 20% have opted to, says Amy McHugh, a spokeswoman for the Massachusetts insurer.
Had it done nothing, the Blue Cross Blue Shield insurer projects its GLP-1 costs would run close to $1 billion this year, nearly double its costs in 2025 and seven times the $140 million it spent in 2023. That “would mean significantly higher premiums for everyone, whether they use these medications or not,” McHugh adds.
The Wall Street Journal (free link)
Supporters of these medications point to the impressive weight-loss results many people achieve. People who have struggled with obesity for years have lost significant amounts of weight and seen improvements in their overall health. One woman interviewed for the article reported losing 130 pounds while using GLP-1 medications.
Many employers that continue covering the drugs have begun attaching requirements to maintain access. Workers may have to record their weight, track meals, meet with nutritionists, or participate in coaching programs. Samantha Stratton, one of the employees featured in the article, acknowledged that “the structure has helped her stick to the regimen.”
The discussion surrounding GLP-1 drugs often focuses on the medication itself while overlooking the habits that surround successful weight management. A person who pays attention and sticks to a plan has adopted behaviors that become lifelong. Medication may help control appetite, but daily routines are the cement that hold the bricks of health together.
I believe sustainable health comes from sustainable behavior. People do not gain weight because they suffer from a shortage of pharmaceuticals. Generally, weight gain develops over years of poor food choices, sedentary lifestyles, and yo-yo dieting. The solution isn’t found dramatic diets or extreme exercise programs… and especially not found in long-term and expensive pharmaceutical interventions. Lasting health comes from restoring balance and consistency to everyday decisions.
There are people with severe obesity, metabolic disorders, or medical conditions that warrant pharmaceutical treatment. I don’t dispute that. Medicine has an important role in modern healthcare. The concern is when pharmaceutical intervention becomes the default answer to problems that originated from lifestyle choices. A society that reaches for a prescription before addressing behavior is treating symptoms while leaving underlying causes untouched.
Employers are discovering that widespread dependence on expensive medications creates its own set of challenges. Current GLP-1 prices range from discounted programs costing a few hundred dollars per month to list prices exceeding $1,000 monthly. Pharmaceutical manufacturers are creating new programs for employers because traditional insurance coverage has reached a breaking point for many organizations. Companies are forced to ask how much they can spend to manage a problem that never should have reached this scale and is really not their problem. This isn’t cancer treatment.
Even the strongest arguments in favor of GLP-1 coverage rely on future savings. Executives cited in the article believe lower obesity rates could reduce healthcare spending over time. Those projections depend on long-term use and don’t take into consideration unknown long-term side effects that have yet to emerge.
People need to choose a different path. Instead of focusing on how to finance lifelong treatment, ask how you can avoid needing treatment in the first place. But, there is no billion-dollar marketing campaign behind figuring out what actually works for you, eating whole fresh food and getting in at least 30 minutes of exercise a day.
Many of the requirements employers are imposing on GLP-1 users are the same practices that have supported healthy weight management long before the first GLP-1 injection reached the market. Employers are spending billions on medications while also requiring participants to follow the very behaviors that health advocates have promoted all along.
The lesson from this highlights our tendency to search for technological solutions to problems rooted in human behavior. The result is a cycle in which people become dependent on increasingly expensive interventions while the habits that created the problem remain unchanged. People need to fix the root of the problem or the weed will just grow back.
Leave a Reply